R 61837: antirhinovirus cpd; structure given in first source
ID Source | ID |
---|---|
PubMed CID | 127504 |
CHEMBL ID | 1233737 |
SCHEMBL ID | 992823 |
MeSH ID | M0160622 |
Synonym |
---|
CHEMBL1233737 |
r-61837 |
3-methoxy-6-[4-(m-tolyl)piperazin-1-yl]pyridazine |
5-(trifluoromethyl)-3-[3,5-dimethyl-4-[[3-(3-methyl-5-isoxazolyl)propyl]oxy]phenyl]-1,2,4-oxadiazole |
r 61837 |
JEN , |
3-methoxy-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine |
DB08017 |
3-methoxy-6-[4-(3-methylphenyl)piperazin-1-yl]pyridazine |
pyridazine, 3-methoxy-6-(4-(3-methylphenyl)-1-piperazinyl)- |
3-methoxy-6-(4-(3-methylphenyl)-1-piperazinyl)pyridazine |
100241-46-1 |
unii-hk76he61aq |
hk76he61aq , |
DDOAUTHWSCUHQA-UHFFFAOYSA-N |
SCHEMBL992823 |
DTXSID30143050 |
r61837 |
3-methoxy-6-(4-(3-methylphenyl)piperazin-1-yl)pyridazine |
Q27097247 |
3-methoxy-6-(4-(m-tolyl)piperazin-1-yl)pyridazine |
AKOS040747335 |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1562994 | Antiviral activity against Rhinovirus at 32 uM relative to control | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (36.36) | 18.7374 |
1990's | 6 (54.55) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (9.09) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.85) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (9.09%) | 5.53% |
Reviews | 1 (9.09%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (81.82%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |